References
- Hirose S, Hamashima Y. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome. A skin biopsy study of 27 patients. Eur J Pediatr 1978;129: 17-27 https://doi.org/10.1007/BF00441370
- Brendel-Muller K, Hahn A, Schneppenheim R, Santer R. Laboratory signs of activated coagulation are common in Henoch-Schonlein purpura. Pediatr Nephrol 2001;16:1084-8 https://doi.org/10.1007/s004670100033
- Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996;75:892-8
- Sakai M, Asayama K, Otabe T, Kohri T, Shirahata A. Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease. Clin Appl Thromb Hemost 2001;7: 214-8 https://doi.org/10.1177/107602960100700306
- Imamura T, Yoshihara T, Yokoi K, Nakai N, Ishida H, Kasubuchi Y. Impact of increased D-dimer concentrations in Kawasaki disease. Eur J Pediatr 2005;164:526-7 https://doi.org/10.1007/s00431-005-1699-7
- Lin MT, Tsao LY, Cheng ML, Chang YJ, Chiu HY, Chen HN, et al. Absence of hypercoagulability in acute Kawasaki disease. Pediatr Int 2005;47:126-31 https://doi.org/10.1111/j.1442-200x.2005.02025.x
- Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, Tokyo 1984
- Cotran RS, Pober JS. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990;1:225-35
- Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Jr., Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988;263:5797- 803
- Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/ fibrin degradation products in hypercoagulable states. Br J Haematol 1989;71:65-70 https://doi.org/10.1111/j.1365-2141.1989.tb06276.x
- Egermayer P, Town GI, Turner JG, Heaton DC, Mee AL, Beard ME. Usefulness of D-dimer, blood gas, and respiratory rate measurements for excluding pulmonary embolism. Thorax 1998;53:830-4 https://doi.org/10.1136/thx.53.10.830
- de Moerloose P, Desmarais S, Bounameaux H, Reber G, Perrier A, Dupuy G, et al. Contribution of a new, rapid, individual and quantitative automated D-dimer ELISA to exclude pulmonary embolism. Thromb Haemost 1996;75:11-3
- Beckham JC, Caldwell DS, Peterson BL, Pippen AM, Currie MS, Keefe FJ, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61 https://doi.org/10.1007/BF00920793
- Burns JC, Glode MP, Clarke SH, Wiggins J, Jr., Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 1984;105:206-11 https://doi.org/10.1016/S0022-3476(84)80114-6
- Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, et al. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy. Pediatr Res 2003;53:983-8 https://doi.org/10.1203/01.PDR.0000061566.63383.F4
- Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33 https://doi.org/10.1542/peds.2004-2182
- Mitani Y, Sawada H, Hayakawa H, Aoki K, Ohashi H, Matsumura M, et al. Elevated levels of high-sensitivity Creactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005;111:38-43 https://doi.org/10.1161/01.CIR.0000151311.38708.29
- Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gammaglobulin treatment in Kawasaki disease. J Pediatr 2000;137: 177-80 https://doi.org/10.1067/mpd.2000.107890
- Hidaka T, Nakano M, Ueta T, Komatsu Y, Yamamoto M. Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease. J Pediatr 1983;102:94-6 https://doi.org/10.1016/S0022-3476(83)80300-X